These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 39380910)

  • 1. Mining and evaluation of adverse event signals for capmatinib based on the FAERS database.
    Chen X; Jiang Y; Zhu H; Tian M
    Front Pharmacol; 2024; 15():1417661. PubMed ID: 39380910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety evaluation of ceftazidime/avibactam based on FAERS database.
    Zhang X; Jiang Y; Guo Y; Zhou W; Qiao W; Zhu H; Qi Z
    Infection; 2024 Jun; ():. PubMed ID: 38842750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study.
    Wu J; Wu J; Tang B; Wang X; Wei F; Zhang Y; Li L; Li H; Wang B; Wu W; Hong X
    Front Pharmacol; 2024; 15():1399172. PubMed ID: 39309013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system.
    Zhao J; Tao Y
    Front Pharmacol; 2024; 15():1393940. PubMed ID: 39185318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database.
    Jiang Y; Cheng Y; Du Z; Shen Y; Zhou Q; Ji Y; Zhu H
    J Psychopharmacol; 2024 Jun; 38(6):567-578. PubMed ID: 38678377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system.
    Wang Y; Liu X
    Front Pharmacol; 2024; 15():1392263. PubMed ID: 39193332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Shu Y; Ding Y; Liu Y; Wu P; He X; Zhang Q
    Front Pharmacol; 2022; 13():862508. PubMed ID: 35754494
    [No Abstract]   [Full Text] [Related]  

  • 8. Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database.
    Hu Y; Du Y; Qiu Z; Zhu C; Wang J; Liang T; Liu T; Da M
    Front Pharmacol; 2024; 15():1399998. PubMed ID: 39108741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the safety of bedaquiline: insight from adverse event reporting system analysis.
    Wu J; Pan H; Shen L; Zhao M
    Front Pharmacol; 2024; 15():1382441. PubMed ID: 38783951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database.
    Zhu H; Qu Y; Du Z; Zhou Q; Shen Y; Jiang Y; Zhou Z; Zhou H
    J Affect Disord; 2024 Feb; 347():45-50. PubMed ID: 37992768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unveiling the adverse events of Nusinersen in spinal muscular atrophy management based on FAERS database.
    Jiang Y; Shen Y; Zhou Q; Zhu H
    Sci Rep; 2024 Jul; 14(1):17138. PubMed ID: 39060346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of adverse events associated with pimavanserin using the FAERS database.
    Gu J; Qu Y; Shen Y; Zhou Q; Jiang Y; Zhu H
    J Affect Disord; 2024 Oct; 362():742-748. PubMed ID: 39029673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database.
    Zhu J; Hu M; Liang Y; Zhong M; Chen Z; Wang Z; Yang Y; Luo Z; Zeng W; Li J; Du Y; Liu Y; Yang C
    Heliyon; 2024 Jul; 10(14):e34837. PubMed ID: 39149028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1).
    Tang H; Xu J; Zhang X; Chen C; Song G; Ma R; Zhao J; Zhao Q
    Front Pharmacol; 2024; 15():1463560. PubMed ID: 39372199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database.
    Li Z; Guo C; Liu X; Qiu Z; Zhang R
    Front Pharmacol; 2024; 15():1368763. PubMed ID: 38549677
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database.
    Li S; Huang R; Meng Y; Liu Y; Qian J; Zou J; Yang J
    Front Pharmacol; 2024; 15():1420126. PubMed ID: 39161895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database.
    Zhang Y; Zhou C; Liu Y; Hao Y; Wang J; Song B; Yu J
    Front Pharmacol; 2024; 15():1472648. PubMed ID: 39376606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical adverse events to dexmedetomidine: a real-world drug safety study based on the FAERS database.
    Liu F; Zheng JX; Wu XD
    Front Pharmacol; 2024; 15():1365706. PubMed ID: 39015372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database.
    Yu M; Zhou L; Cao M; Ji C; Zheng Y
    Front Immunol; 2024; 15():1397692. PubMed ID: 39234238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023.
    Xiong S; Gou R; Liang X; Wu H; Qin S; Li B; Luo C; Chen J
    Diabetes Ther; 2024 Aug; 15(8):1717-1733. PubMed ID: 38776037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.